Terms: = Lymphoma AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Treatment
22278 results:
1. [UPLC-QE-Orbitrap-MS combined with network pharmacology to explore differential components and mechanisms of raw and scorched rhubarb for treatment of ulcerative colitis].
Sun J; Xu WJ; Zhong LY; Chen JB; Dong L
Zhongguo Zhong Yao Za Zhi; 2024 Apr; 49(7):1834-1847. PubMed ID: 38812196
[TBL] [Abstract] [Full Text] [Related]
2. A retrospective analysis of the incidence and risk factors of perioperative urinary tract infections after total hysterectomy.
Cao X; Tu Y; Zheng X; Xu G; Wen Q; Li P; Chen C; Yang Q; Wang J; Li X; Yu F
BMC Womens Health; 2024 May; 24(1):311. PubMed ID: 38811924
[TBL] [Abstract] [Full Text] [Related]
3. [Prognostic analysis of childhood T-lymphoblastic lymphoma treated with leukemia regimen].
Hou SM; Shao JB; Li H; Zhang N; Zhu JS; Wang D; Fu P
Zhongguo Dang Dai Er Ke Za Zhi; 2024 May; 26(5):469-475. PubMed ID: 38802906
[TBL] [Abstract] [Full Text] [Related]
4. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.
Dupuis J; Bachy E; Morschhauser F; Cartron G; Fukuhara N; Daguindau N; Casasnovas RO; Snauwaert S; Gressin R; Fox CP; d'Amore FA; Staber PB; Tournilhac O; Bouabdallah K; Thieblemont C; André M; Rai S; Ennishi D; Gkasiamis A; Nishio M; Fornecker LM; Delfau-Larue MH; Sako N; Mule S; de Leval L; Gaulard P; Tsukasaki K; Lemonnier F
Lancet Haematol; 2024 Jun; 11(6):e406-e414. PubMed ID: 38796193
[TBL] [Abstract] [Full Text] [Related]
5. Two cases of inflammatory myofibroblastic tumor treated with targeted drugs: A case report.
Liu M; Zhu D
Medicine (Baltimore); 2024 May; 103(21):e38136. PubMed ID: 38787978
[TBL] [Abstract] [Full Text] [Related]
6. Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin lymphoma or Peripheral T-Cell lymphoma: A Retrospective United States Claims Analysis.
Sano D; Liu N; Knowles S; MacEwan JP; Wang S; Wogen J; Yu KS; Lee ST
Curr Oncol; 2024 May; 31(5):2598-2609. PubMed ID: 38785476
[TBL] [Abstract] [Full Text] [Related]
7. Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair.
Ida N; Okura M; Tanaka S; Hosono N; Yamauchi T
Oncol Rep; 2024 Jul; 52(1):. PubMed ID: 38785163
[TBL] [Abstract] [Full Text] [Related]
8. The efficiency and safety of temozolomide and PD-1/L1 inhibitors in pretreated NSCLC with brain metastasis: a retrospective cohort.
Li X; Wu D; Tang J; Wu Y
J Cancer Res Clin Oncol; 2024 May; 150(5):271. PubMed ID: 38780840
[TBL] [Abstract] [Full Text] [Related]
9. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor.
Salem AH; Menon RM
Clin Transl Sci; 2024 May; 17(5):e13807. PubMed ID: 38778732
[TBL] [Abstract] [Full Text] [Related]
10. A retrospective study of an irradiation-based conditioning regimen and chidamide maintenance therapy in T-ALL/LBL.
Wang X; Deng Y; He G; Lai S; Li Y; Zhang S; He Y; Han Y; Zhang L; Su Y; Liu F; Yi H
Hematology; 2024 Dec; 29(1):2356300. PubMed ID: 38776229
[TBL] [Abstract] [Full Text] [Related]
11. Observation of lymphadenopathy, systemic symptoms, and treatment in suspected indolent cutaneous B-cell lymphomas.
Puccio J; Huang Y; Viveiros MD; Reneau JC; Chung C; Spaccarelli N; Dulmage B
Arch Dermatol Res; 2024 May; 316(5):199. PubMed ID: 38775835
[TBL] [Abstract] [Full Text] [Related]
12. Semimethylation is a feature of diffuse large B-cell lymphoma, and subgroups with poor prognosis are characterized by global hypomethylation and short telomere length.
Carlund O; Thörn E; Osterman P; Fors M; Dernstedt A; Forsell MNE; Erlanson M; Landfors M; Degerman S; Hultdin M
Clin Epigenetics; 2024 May; 16(1):68. PubMed ID: 38773655
[TBL] [Abstract] [Full Text] [Related]
13. Surgical outcomes of robotic thyroidectomy for thyroid tumors over 4 cm via the bilateral axillo-breast approach.
Bae HL; Wong JS; Kim SJ; Jung Y; Choi JB; Kwak J; Yu HW; Chai YJ; Choi JY; Lee KE
Sci Rep; 2024 May; 14(1):11646. PubMed ID: 38773181
[TBL] [Abstract] [Full Text] [Related]
14. Proteomic characterization and cytotoxic potential of proteins from Cuscuta (Cuscuta epithymum (L.) crude herbal product against MCF-7 human breast cancer cell line.
Akhtar U; Khurshid Y; El-Aarag B; Syed B; Khan IA; Parang K; Ahmed A
BMC Complement Med Ther; 2024 May; 24(1):195. PubMed ID: 38769554
[TBL] [Abstract] [Full Text] [Related]
15. Fertility preservation in female cancer patients in Brazil: perceptions and attitudes of infertility specialists.
Ranniger RL; Lamaita RM; D'Abreu BF; Tolentino MR; Cândido EB; Andrade WP; Nogueira-Rodrigues A; Silva-Filho AL
Rev Bras Ginecol Obstet; 2024; 46():. PubMed ID: 38765513
[TBL] [Abstract] [Full Text] [Related]
16. Efficacy and safety of netupitant/palonosetron in preventing nausea and vomiting in diffuse large B cell lymphoma patients undergoing R-CHOP chemotherapy.
Kwak K; Park Y; Kim BS; Kang KW
Sci Rep; 2024 May; 14(1):11229. PubMed ID: 38755279
[TBL] [Abstract] [Full Text] [Related]
17. Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study.
Gao Y; He H; Li X; Zhang L; Xu W; Feng R; Li W; Xiao Y; Liu X; Chen Y; Wang X; Bai B; Wu H; Cai Q; Li Z; Li J; Lin S; He Y; Ping L; Huang C; Mao J; Chen X; Zhao B; Huang H
Signal Transduct Target Ther; 2024 May; 9(1):121. PubMed ID: 38755119
[TBL] [Abstract] [Full Text] [Related]
18. Evaluation of sex inequity in lung-cancer-specific survival.
Lærum D; Strand TE; Brustugun OT; Gallefoss F; Falk R; Durheim MT; Fjellbirkeland L
Acta Oncol; 2024 May; 63():343-350. PubMed ID: 38751329
[TBL] [Abstract] [Full Text] [Related]
19. Baseline immunoglobulin G and immune function in non-Hodgkin lymphoma: a retrospective analysis.
Brazel D; Grant C; Cabal A; Chen WP; Pinter-Brown L
Front Immunol; 2024; 15():1334899. PubMed ID: 38745669
[TBL] [Abstract] [Full Text] [Related]
20. M6A-induced transcription factor IRF5 contributes to the progression of cervical cancer by upregulating PPP6C.
Hou PX; Fan Q; Zhang Q; Liu JJ; Wu Q
Clin Exp Pharmacol Physiol; 2024 Jul; 51(7):e13868. PubMed ID: 38745265
[TBL] [Abstract] [Full Text] [Related]
[Next]
